Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top EstimatesZacks Investment Research • 03/13/24
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business UpdateGlobeNewsWire • 03/13/24
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024GlobeNewsWire • 03/06/24
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsGlobeNewsWire • 02/28/24
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/31/24
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsGlobeNewsWire • 01/02/24
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023GlobeNewsWire • 11/06/23
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 11/03/23
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerGlobeNewsWire • 11/01/23
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to BuyZacks Investment Research • 10/18/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 10/11/23
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor ConferenceGlobeNewsWire • 09/20/23
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/29/23
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundZacks Investment Research • 08/22/23
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/23
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023GlobeNewsWire • 08/03/23
Spero Therapeutics shares rise on FDA approval of pivotal complicated UTI trialProactive Investors • 07/31/23
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBrGlobeNewsWire • 07/31/23